101Bio品牌國內(nèi)代理商---默瑞生物

101Bio針對細胞培養(yǎng)上清，血漿/血清，干細胞培養(yǎng)上清，尿液及其他體液的外泌體提取試劑盒、3D細胞培養(yǎng)基凝膠等。

We help our customers to assemble SARS-CoV and SARS-CoV-2 S protein pseudotyped lentiviruses. These particles carry reporters that can be used for antiviral drug screening or the quantification of neutralizing antibodies. Use reporter construct from customer, and we can assemble particles within 1-2 weeks. 可用于抗病毒藥物篩選或中和抗體的定量。

We also offer 6 pre-assembled, concentrated (60 x concentrated) particles for your initial testing (see table below). Our proprietary SARS-CoV-2 Pseudovirus Infection Enhancer (Cat#: CoV2-1ml) can greatly promote productive viral infection. This enhancer is used to facilitate the infection of a variety of host cells and enhance viral infection rates by 5 to 20 folds（假病毒感染增強劑用于多種宿主細胞的感染，并將病毒感染率提高5-20倍）.

1) The SARS-CoV-2 S protein pseudotyped lentiviral particles naturally have much lower infectivity than SARS-CoV S protein pseudotyped particles. The GFP reporter virus is designed for use in microscope imaging studies of GFP positive cells.

SARS-CoV-2 S 蛋白假型慢病毒比 SARS-CoV S 蛋白假型慢病毒擁有更低的傳染性，GFP報告病毒用于GFP陽性細胞的顯微成像研究。

2) Use our enhancer(Cov2-1ml ) for Luc virus to get robust signal. This enhancer works perfect for the SARS-CoV-2 S protein pseudotyped Luc (luciferase) reporter virus so it can effectively infect cells that naturally express ACE2 (such as Vero E6 cells). There is no need to over-express ACE2 in target cells by transient DNA transfection (see Fig. 1).

使用Luc病毒增強劑（Cov2-1ml）獲得穩(wěn)健的信號。這種增強劑對SARS-CoV-2s蛋白假型Luc（luciferase熒光素酶）報告病毒非常有效，因此它能有效感染自然表達ACE2的細胞（如Vero E6細胞）。瞬時DNA轉(zhuǎn)染不需要在靶細胞中過度表達ACE2

3) The Luc reporter is expressed from the HIV-1 LTR promoter, which is driven by co-expression of the Tat protein that is present only in infected cells. The Luc reporter system is more robust than common promoters used for reporter expression.

       Luc報告者是從HIV-1ltr啟動子中表達的，該啟動子由僅存在于受感染細胞中的Tat蛋白共同表達驅(qū)動。Luc報告程序系統(tǒng)比用于報告程序表達式的普通啟動程序更健壯。

Lenti-pseudovirus infection of Vero E6 cells (applicable to SARS-CoV S, SARS-CoV-2 S, and VSV-G pseudotyped viruses)

1) Count Vero E6 cells to be infected and seed ~1 x 105 cells per well into 12-well plates (0.5 ml per well). Culture cells until cells stably adhere to the plates (4–12 hours).Note: Cell viability should be ≥ 80%.

2) Before infection, wash cells with 2 ml medium, and leave 250 μl medium in each well.

3) Pre-treat cells by adding 25 μl of pseudovirus infection enhancer (Cat# CoV2-1ml) (10 X) so that the

enhancer concentration is 1 X. Mix and incubate for 30–60 minutes.

4) Add virus to the cells and mix. Note volume of virus used.

5) Add infection enhancer (10 X) in an amount equal to 1/10 of the virus volume used, e.g., if 100

μl of virus is used, add 10 μl of infection enhancer. Incubate at 37°C for 4-6 hours.

6) Add 2 ml fresh media to wash cells.

7) After washing, add 2 ml fresh complete medium.

8) Culture infected cells for 2-3 days to signal detection.

SARS-CoV-2-S(Luc) pseudovirus infection of Vero E6 cells (with pseudovirus infection enhancer ):

Vero E6 cells were transduced with SARS-CoV-2-S(Luc) lenti- pseudovirus (with a luciferase reporter) in the presence or absence of infection enhancer. Reporter expression was quantified at 3 days post transduction (luciferase assay).

60 X concentrated, SARS-CoV and SAR-CoV-2 pseudoviral particles

SARS-CoV-2 S protein pseudotyped lentiviral particle transduction of Vero E6 cells (Left):

Vero E6 cells were transduced with SARS-CoV-2- S(Luc) lenti-pseudovirus (with a luciferase reporter) in the presence of CoV-2-PIE. Reporter expression was quantified at 3 days post transduction (luciferase assay).

SARS-CoV S protein pseudotyped lentiviral particle transduction of Vero cells (Right):

Vero cells were transduced with SARS-CoV-S(GFP) lenti-pseudovirus (with a GFP reporter) in the presence of CoV-2-PIE. Reporter expression was quantified at 2 days post transduction (GFP flow cytometry).

SARS-CoVandSARS-CoV-2pseudovirus transduction of target cells for viral entry and functional studies.

Anti-SARS-CoV and SARS-CoV-2 drug screening

Anti-SARS-CoVandSARS-CoV-2 neutralizing antibody screening SARS-CoV and CoV-2 pseudoviruses are intended for Research Use Only.

HIV Rev-dependent Reporter Cells (Cat.# HRC-1) and HIV infection enhancer (H901-1)

Real 3D Cell Culture Gel Col-Tgel (Cat.# P720)

Lentivirus / Retrovirus  10X Titer-Up Reagent  (Cat.# P906 / P909)95% pure Exosome Isolation kits 

默瑞(上海)生物科技有限公司，作為專業(yè)的生命科學產(chǎn)品推廣與服務(wù)商，以“創(chuàng)新，專業(yè)，共贏”的理念，不斷強化服務(wù)體系，提升客戶體驗，以莫納生物產(chǎn)品為主線，結(jié)合國內(nèi)外優(yōu)質(zhì)產(chǎn)品提供高標準完整解決方案，幫助科研客戶和生物技術(shù)企業(yè)高效創(chuàng)新，加速轉(zhuǎn)化，創(chuàng)造更多優(yōu)質(zhì)產(chǎn)品，提升社會福祉，實現(xiàn)多方共贏。

默瑞生物創(chuàng)立以來，已經(jīng)陸續(xù)導入

TwistDx,101Bio,enzymatics,AATBioquest,KAPABIOSYSTEMS,BioDynami,Jackson,Echelon,ChromoTek,Nanocs,Biotechrabbit,LeeBiosolutions, magtivio等優(yōu)質(zhì)國際品牌，逐步培育成為專業(yè)用戶的首選。